Welcome to Nutraceuticals World   
October 2014 Issue
Last Updated Wednesday, October 22 2014
Print

Oragenics Obtains U.S. Patent for IVIAT



Published October 17, 2011
Related Searches: Proteins
Oragenics, Inc., Tampa, FL, has been issued patent No. 8,034,571 from the U.S. Patent and Trademark office for In Vivo Induced Antigen Technology (IVIAT). This platform technology is a novel approach for studying microbial pathogenesis that identifies genes of a pathogenic organism, which are differentially expressed during an actual human infection. IVIAT can be applied to all pathogenic bacteria, yeasts and parasites to rapidly identify proteins that are expressed when a pathogen infects a human. Such proteins are excellent targets for medical diagnostics and therapeutic strategies.


Receive free Nutraceuticals World emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Nutraceuticals World On